<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04082325</url>
  </required_header>
  <id_info>
    <org_study_id>18144A</org_study_id>
    <nct_id>NCT04082325</nct_id>
  </id_info>
  <brief_title>Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men</brief_title>
  <official_title>Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-oral-dose Study Investigating the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Properties of Lu AF88434 and Open-label Crossover Study to Investigate the Intra-individual Variability, Metabolic Profile, and Effect of Food on Lu AF88434 in Healthy Young Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of Lu AF88434 on the body and what the body does to Lu
      AF88434 and the effect of food after swallowing single oral doses
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2019</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events</measure>
    <time_frame>From screening to Day 11</time_frame>
    <description>Safety and tolerability based on the safety assessments (clinical safety laboratory tests, vital signs, weight, ECG parameters)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax Lu AF88434</measure>
    <time_frame>From 0 to 96 hours</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf) Lu AF88434</measure>
    <time_frame>From 0 to 96 hours</time_frame>
    <description>Area under the plasma concentration time curve from zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F Lu AF88434</measure>
    <time_frame>From day 1 to day 5</time_frame>
    <description>Oral clearance for Lu AF88434 in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative recovery of radioactivity in urine, faeces, and total (urine+faeces) (% of administered dose)</measure>
    <time_frame>From 0 to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total recovery of radioactivity in urine, faeces, and total (urine+faeces) (% of administered dose)</measure>
    <time_frame>From 0 to Day 14</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A Lu AF88434 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 cohorts (cohort A1 to A6) with 9 subjects in each cohort. In each cohort 6 subjects will receive single doses of Lu AF88434 and 3 subjects will receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B1 Lu AF88434 Fed-Fasting-Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 subjects will receive an identical oral dose of Lu AF88434 in Group B1. The treatment sequence for Group B1 is: Fed-Fasting-Fasting. 14C-spiked dose (Lu AF99723) will be given in the last treatment sequence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B2 Lu AF88434 Fasting-Fed-Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 subjects will receive an identical oral dose of Lu AF88434 in Group B2. The treatment sequence for Group B2 is: Fasting-Fed-Fasting. 14C-spiked dose (Lu AF99722) will be given in the last treatment sequence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B3 Lu AF88434 Fasting-Fasting-Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 subjects will receive an identical oral dose of Lu AF88434 in Group B3. The treatment sequence for Group B3 is: Fasting-Fasting-Fed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF88434</intervention_name>
    <description>Lu AF88434, single oral solution Starting dose will be 0.2 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).</description>
    <arm_group_label>Part A Lu AF88434 or Placebo</arm_group_label>
    <arm_group_label>Part B1 Lu AF88434 Fed-Fasting-Fasting</arm_group_label>
    <arm_group_label>Part B2 Lu AF88434 Fasting-Fed-Fasting</arm_group_label>
    <arm_group_label>Part B3 Lu AF88434 Fasting-Fasting-Fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434)</intervention_name>
    <description>Oral solution</description>
    <arm_group_label>Part B2 Lu AF88434 Fasting-Fed-Fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434)</intervention_name>
    <description>Oral solution</description>
    <arm_group_label>Part B1 Lu AF88434 Fed-Fasting-Fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to Lu AF88434 oral solution, single dose</description>
    <arm_group_label>Part A Lu AF88434 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Healthy young non-smoking men with a body mass index (BMI) ≥18.5kg/m2 and ≤30kg/m2 at the
        Screening Visit and Baseline Visit.

        Exclusion Criteria:

          -  The subject has or has had any clinically significant immunological, cardiovascular,
             respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological,
             haematological, dermatological, venereal, neurological, or psychiatric disease or
             other major disorder.

          -  For Part B: The subject has received radiolabelled material &lt;12 months prior to the
             Screening Visit.

        Other inclusion and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>QPS</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Email contact via H. Lundbeck A/S</last_name>
      <phone>+45 36301311</phone>
      <email>LundbeckClinicalTrials@Lundbeck.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

